Breast cancer is the most common cancer among American women, whereas Asian women, who consume a traditional diet high in soy products, have a relatively low incidence. Genistein is a prominent iso¯avonoid in soy products and has been proposed as the agent responsible for lowering the rate of breast cancer in Asian women. We investigated the eects of genistein on cell growth and apoptosis-related gene expression in breast cancer cells MDA-MB-231. We found upregulation of Bax and p21 WAF1 expressions and downregulation of Bcl-2 and p53 expression in genisteintreated cells. Furthermore, DNA ladder formation, CPP32 activation, and PARP cleavage were observed after treatment with genistein, indicating apoptotic cell deaths. Flow cytometry with 7-amino actinomycin D staining showed that the number of apoptotic cells increased with longer treatment of genistein. From these results, we conclude that genistein inhibits the growth of MDA-MB-231 breast cancer cells, regulates the expression of apoptosis-related genes, and induces apoptosis through a p53-independent pathway. The up-regulation of Bax and p21 WAF1 may be the molecular mechanisms by which genistein induces apoptosis, however, further de®nitive studies are needed. These results suggest that genistein may be a potentially eective chemopreventive or therapeutic agent against breast cancer.
Introduction
Breast cancer is the most common cancer among American women, and remains the second leading cause of cancer related deaths in US females (Parker et al., 1996) . In contrast, Asian women, who consume a traditional diet high in soy products, have a relatively low incidence of breast cancer. Asians who immigrate to the United States and adopt a Western diet are at higher risk of breast cancer (Lee et al., 1991; Adlercreutz et al., 1991) . Epidemiological studies reveal that soy-based diets containing iso¯avonoid may reduce the risk of certain hormone-dependent cancers such as breast, prostate and colon cancer (Lee et al., 1991; Messina et al., 1991 Messina et al., , 1994 Yuan et al., 1995; Gescher et al., 1998) . The much lower risk of breast, colon, and prostate cancers in Asians, who consume 20 ± 50 times more soy than Americans, has raised the question whether compounds in the soy diet act as a natural chemopreventive agent. Soy-based diets are high in iso¯avonoid. Genistein is a prominent iso¯avonoid in soy products and has been proposed as the agent responsible for lowering the rate of breast cancer in Asian women (Lamartiniere et al., 1995; Fotsis et al., 1995) . The mechanism for this chemopreventive eect, however, is unknown.
Genistein has been identi®ed as a protein tyrosine kinase (PTK) inhibitor (Akiyama et al., 1987) . PTKs are known to play a key role in oncogenesis, control of cell growth, and apoptosis (Hunter, 1987; Morla et al., 1989; Ullrich and Schlessinger, 1990; Kyle et al., 1997) . It has been reported that genistein is a potent inhibitor of cell proliferation, oncogenesis and clonogenic ability in animal and human cells (Fotsis et al., 1995; Barnes, 1995) . Genistein also inhibits the growth of carcinogeninduced cancers in rats and human leukemia cells transplanted into mice (Lamartiniere et al., 1995; Uckun et al., 1995) . The induction of stress proteins (e.g. glucose-related proteins and heat shock proteins) in tumor cells has been shown to protect them against apoptosis. This stress response is inhibited by genistein (Zhou and Lee, 1998) . Genistein has been shown to induced apoptosis in prostate cancer and leukemia cells (Kyle et al., 1997; Spinozzi et al., 1994) . Furthermore, studies with MCF7 breast cancer cells containing functional ER and wild type p53 also showed cell growth inhibition and apoptosis (Shao et al., 1998; Wang et al., 1996 Wang et al., , 1997 . The role of genistein in changing the expression of genes involved in the apoptotic pathway, however, is less well documented.
The molecular mechanism implicated in apoptosis has been partially elucidated. The induction of apoptosis is partly mediated, intracellularly by several genes, such as p53, Bcl-2, Bax, and p21 WAF1 (Chiarugi et al., 1994) . The p53 tumor suppressor gene is a cell cycle regulator able to induce cell cycle arrest to allow DNA repair or apoptosis (Vogelstein and Kinzler, 1992) . p21 WAF1 is activated by the p53 protein, and an increased level of p21 WAF1 is associated in cyclincontaining complexes with decreasing cyclin-dependent activity in damaged cells destined to apoptosis (El-Deiry et al., 1993; Harper et al., 1993) . Although its mechanism of action is still unclear, Bcl-2 functions as a suppressor of apoptotic death triggered by a variety of signals (Sedlak et al., 1995) , and is negatively regulated by wild type p53. Bcl-2 overexpression has been shown to inhibit apoptosis induced by a variety of stimuli, whereas, a predominance of Bax over Bcl-2 accelerates apoptosis upon apoptotic stimuli (Williams and Smith, 1993) .
The purpose of our study was to investigate the molecular mechanism by which genistein exerts its inhibitory eects on a breast cancer cell line containing mutant p53 and lacking functional ER (MDA-MB-231), and to provide the scienti®c rationale for using genistein as a chemopreventive or therapeutic agent against breast cancer. Our data show that genistein induced apoptosis with alterations of apoptosis-related gene expressions in MDA-MB-231 breast cancer cells.
Results

Eects of genistein on cell growth
The treatment of MDA-MB-231 breast cancer cells for 1 ± 6 days with 5, 15 and 30 mM of genistein resulted in inhibition of cell proliferation. The inhibition of cell proliferation is dose-dependent. The eect of genistein on the cell growth of MDA-MB-231 is depicted in Figure 1 . Inhibition of cell proliferation could be the result of the induction of apoptosis, cell cycle growth arrest and/or the inhibition of growth. We therefore, investigated whether genistein could induce apoptosis in breast cancer cells.
Induction of apoptosis
Apoptosis was observed in the cells treated with 30 mM genistein as illustrated by the DNA ladder shown in Figure 2a . The induction of apoptosis was more pronounced at 48 ± 72 h of treatment, and is directly correlated with the inhibition of cell growth. Western blot analysis of PARP cleavage showed that the PARP protein was degraded, with the concomitant diminution of full size (116 KD) molecule and accumulation of the 85 KD, in cells after 48 h of genistein treatment (Figure 2b ). Western blot analysis of CPP32 activation also showed that the CPP32 protein was cleaved to yield a 17 KD fragment after treatment of genistein ( Figure 2c ). These data provide strong evidence that apoptosis was induced in cells treated with genistein.
Furthermore,¯ow cytometry data with 7-amino actinomycin D staining showed increased apoptotic cells after genistein treatment for 24 h (13%), 48 h (29.16%) and 72 h (43.04%), compared to the control sample (7.01%) (Figure 2d ). These four independent methods of measuring apoptosis provided similar results, suggesting that genistein induces apoptosis in breast cancer cells in addition to cell growth inhibition. These results, however, do not provide any evidence regarding the mechanism by which genistein induces apoptosis. In order to explore such mechanisms, we investigated the alterations in the expression of the genes involved in the apoptotic pathway.
Expression of p21 WAF1
The expression of p21 WAF1 in MDA-MB-231 cells was investigated in genistein-treated and -untreated cells by Western blot analysis. The results of a typical experiment are shown in Figure 3a , which demonstrates the induction of p21 WAF1 protein when cells were treated with 30 mM genistein for 24 h. A similar induction was also observed when cells were treated with either 5, 15 or 30 mM of genistein for 48 and 72 h. In order to obtain a quantitative value for the protein expression of p21 WAF1 , optical density measurement was conducted as described under Materials and methods. The ratios of p21 WAF1 to actin protein expression revealed that cells treated with genistein showed at least a 1.5-fold increase in p21 WAF1 compared to the untreated control. The induction of p21 WAF1 protein expression was directly correlated with the inhibition of cell growth.
Expression of Bcl-2 and Bax
The constitutive levels of Bcl-2 or Bax and the time course for the eect of genistein on Bcl-2 or Bax expression in MDA-MB-231 cells were studied by Western blot analysis. The levels of Bcl-2 expression in the MDA-MB-231 cells were slightly down-regulated with the addition of 15 or 30 mM of genistein when exposed for 24 ± 72 h. In contrast, the expression of Bax was signi®cantly up-regulated after 24 h of 5, 15 or 30 mM genistein treatment ( Figure 3b ). Optical density measurement was also conducted to obtain a quantitative value for the protein expression of Bax and Bcl-2. The ratios of Bax to Bcl-2 protein expression revealed that cells treated with 30 mM genistein showed at least an 11-fold increase in Bax compared to Bcl-2 at 24 h of treatment, ninefold at 48 h, and fourfold at 72 h ( Figure  3b ). These data suggest that the induction of Bax is transient and rapid, and the eect is diminished at 72 h where 43% of cells underwent apoptotic cell death.
Expression of p53
The expression of p53 in MDA-MB-231 cells with and without genistein treatment was also tested by Western blot analysis. It is important to note that MDA-MB-231 cells possess a mutation in the p53 gene (codon 280, AGA to AAA, Arg to Lys). As shown in Figure  3c , after 24 h of treatment with 30 mM genistein, the levels of mutant p53 protein in MDA-MB-231 cells decreased by about one-third. The expressions of p53 in the cells treated with 5, 15 or 30 mM genistein for 72 h were down-regulated at various degrees. This Figure 1 Cell growth inhibition by genistein result suggests that the down-regulation of mutant p53 may reverse the tumorigenic potential of genistein treated MDA-MB-231 cells, and further in-depth analysis is needed.
Discussion
Experimental studies have shown the inhibition of cell growth of a wide range of cultured cancer cells including leukemia, breast and prostate cancer, and lymphoma by genistein (Constantinou et al., 1990; Barnes, 1991, 1993; Buckley et al., 1993) . Our data also demonstrated that genistein inhibits the growth of MDA-MB-231 breast cancer cells, and that the inhibition is dose-dependent. The decreased cell numbers in the treatment groups compared to the control group may be due to apoptotic cell death as well as cell growth inhibition. Fragmentation of cellular DNA at the internucleosomal linker regions has been observed in cells undergoing apoptosis, which was induced by a variety of agents. This cleavage produces ladders of DNA fragments that are the sizes of integer multiples of a nucleosome length (180 ± 200 bp) (Chiarugi et al., 1994; Huang et al., 1997; Fisher, 1994) . Because of their characteristic patterns revealed by agarose gel electrophoresis, these nucleosomal DNA ladders are widely used as biochemical markers of apoptosis. In addition, the cleavage of poly(ADP-ribose) polymerase (PARP) and the activation of Caspase-3 (CPP32) have also been used as early markers of apoptosis (Lazebnik et al., 1994; Tewari et al., 1995; Darmon et al., 1995) . Additionally,¯ow cytometric analysis with 7AAD staining has now been conducted to detect and quantify apoptotic cells (Philpott et al., 1996) . Using these techniques we, indeed, found induced apoptosis in the MDA-MB-231 breast cancer cells treated with genistein. DNA ladder formation and PARP cleavage were observed in the breast cancer cells after 48 h of treatment with genistein. CPP32 activation was also observed in the breast cancer cells after treatment with genistein. Flow cytometery revealed that the number of apoptotic cells increased from 13% (24 h of treatment) to 43% (72 h of treatment) with longer treatment of genistein). These results suggest that genistein can inhibit the growth of breast cancer cells and induce apoptosis. Our observation is consistent with studies in other cancer cell lines (Kyle et al., 1997; Spinozzi et al., 1994) including MCF7 breast cancer cells as discussed later.
Bax and Bcl-2 have been reported to play a major role in determining whether cells will undergo apoptosis under experimental conditions that promote cell death. Increased expression of Bax can induce apoptosis (Sano et al., 1995; Salomons et al., 1997; Findley et al., 1997) , while Bcl-2 protects cells from apoptosis (Sano et al., 1995; Kane et al., 1994) . Salomons and associates (1997) found that the ratio of Bax : Bcl-2, rather than Bcl-2 alone, is important for the survival of drug-induced apoptosis in leukemia cell lines. Our data showed only a slight decrease of Bcl-2 expression in breast cancer cells after treatment with genistein for 48 h and no change was observed at 24 h. The expressions of Bax, however, were signi®cantly upregulated in breast cancer cells after treatment for 24 h. The ratio of Bax to Bcl-2 was more than 10-fold after 24 h of treatment, corresponding with a signi®cant increase of apoptotic cells after 48 h of genistein treatment. Our results directly corroborate Salomons' conclusion that the ratio of Bax and Bcl-2 protein levels is important for cells undergoing apoptosis. Bax harbors a high homologous sequence with Bcl-2 and forms heterodimers with Bcl-2. Thus, Bax is a protein that antagonizes the anti-apoptotic function of Bcl-2. Our results suggest that up-regulation of Bax and down-regulation of Bcl-2 may be one of the molecular mechanism through which genistein induces apoptosis. However, further in-depth studies are needed in order to establish the role of Bax and Bcl-2 in genisteininduced apoptosis in this system. The p53 and p21 WAF1 tumor suppressor genes are known to be involved in apoptosis. Functional p53 can down-regulate Bcl-2 which allows cells to survive a variety of fatal cellular events and protects cells from apoptosis (Sano et al., 1995; Kane et al., 1994) . Functional p53 can also induce p21
WAF1
, and an increased level of p21 WAF1 can decrease the activity of cyclin-dependent kinases (CDKs), resulting in growth arrest (Vogelstein et al., 1992; El-Deiry et al., 1993; Harper et al., 1993; Agarwal et al., 1995; Xiong et al., 1993) . Hence, functional p53 is important in p53- WAF1 was induced in 24 h. These results suggest that the induction of p21 WAF1 and apoptosis by genistein is through a p53-independent pathway. An increase in p21 WAF1 induced by genistein results in G2 or early M phase arrest, which was reported by our and other laboratories (Lian et al., 1998; Matsukawa et al., 1993) . Cells fail to progress to mitosis and are destined to apoptosis. Thus, the upregulation of p21 WAF1 may be another molecular mechanism through which genistein inhibits cancer cell growth and induces apoptosis. Some researchers have reported that genistein inhibits cell proliferation and induces apoptosis in MCF7 breast cancer cell which is ER-positive and harbors wild type p53 (Shao et al., 1998; Wang et al., 1996 Wang et al., , 1997 . We have similar results with MDA-MB-231 cell which is ER-negative and possesses mutant p53. Therefore, the eects of genistein on cell growth inhibition and induction of apoptosis are independent with ER and p53 status. Thus, on results, together with the results of other investigators, suggest that genistein may aect breast cancer cells irrespective of ER or p53 status.
As a potential chemopreventive or therapeutic agent against breast cancer, genistein have several advantages. It is a natural iso¯avonoid derived from soy products. Other iso¯avonoids in soy proteins may complement genistein in regulating gene expression and inhibiting the growth of pre-cancer and cancer cells. Genistein, even at a high concentration (200 mM), appears to have no toxic eects on mammalian tissue culture cells (Fotsis, 1995) . Our results demonstrated that 5 mM genistein inhibited the growth of breast cancer cells. This concentration of genistein is nearly equivalent to the estimated in vivo concentration (Barnes, 1995) . However, the biological role of iso¯avonoids cannot be directly compared with in vitro experiment, particularly because human are exposed to isoflavonoids chronically, and low concentration in vivo may be equivalent to the higher concentration of iso¯avonoids used in in vitro experiments, where cells are subjected to acute exposure. Thus, low concentration for a long period of time in vivo is equivalent to higher concentration for a short period of time in vitro. In conclusion, our data show that genistein inhibits the growth of breast cancer cells, regulates the expression of apoptosis-related genes, and induces apoptosis in MDA-MB-231 breast cancer cells through a p53-independent pathway. Thus, genistein may be an ideal chemopreventive or therapeutic agent for breast cancer. However, much remains to be studied about the ecacy, concentration, and mechanism of genistein as an anti-cancer agent in vivo.
Materials and methods
Preparation of genistein stock solution for experiments
Genistein powder (Biomol, PA, USA) was dissolved in 0.1 M Na 2 CO 3 solution to make 30 mM genistein stock solution from which dilutions were made for experiments. To test any eect of Na 2 CO 3 on the growth of MDA-MB-231 cells, Na 2 CO 3 solution was added to the cells at the ®nal concentration of 0.1 mM which was the highest concentration of Na 2 CO 3 used in the genistein-treated cell medium. No dierence of cell growth between the MDA-MB-231 cells with and without Na 2 CO 3 was observed, indicating that Na 2 CO 3 did not in¯uence the experiment.
Cell culture and growth inhibition
Human breast cancer cells (MDA-MB-231) were obtained from ATCC and cultured in DMEM/F12 medium (Gibco, MD, USA) supplemented with 10% FBS, 1% penicillin/ streptomycin in a 5% CO 2 atmosphere at 378C. The cells were seeded at a density of 1610 4 /well in a six well culture dish. After 24 h, the cells were treated with 5, 15 and 30 mM of genistein or Na 2 CO 3 (vehicle control). The culture medium was replaced with fresh medium and genistein or Na 2 CO 3 at third day of treatment. Cells treated with genistein or Na 2 CO 3 for 1 to 6 days were harvested by trypsinization, stained with 0.4% trypan blue and counted using a hemacytometer.
Protein extraction and Western blot analysis
The breast cancer cells were plated and culture in complete medium and allowed to attach for 24 h followed by the addition of 5, 15 or 30 mM genistein, and incubation for 24, 48 and 72 h. Control cells were incubated in the medium with Na 2 CO 3 using same time points. After incubation, the cells were harvested by scraping the cells from culture dishes using a scraper and collected by centrifugation. Cells were resuspended in Tris-HCl buer, sonicated for 2610 s and lysed using an equal volume of 4% SDS. Protein concentration was then measured using protein assay reagents (Pierce, IL, USA). Cell extracts were boiled for 10 min and chilled on ice, subjected to 14 or 10% SDS ± PAGE, and electrophoretically transferred to a nitrocellulose membrane. Each membrane was incubated with monoclonal p21 WAF1 (1 : 2000, Upstate, NY, USA), Bcl-2, p53 (1 : 500, Oncogene, MA, USA), Bax (1 : 5000, Biomol, PA, USA), and Polyclonal b-actin (1 : 2000, Sigma, MO, USA) antibodies, washed with TTBS and incubated with secondary antibody conjugated with peroxidase. The signal was then detected using chemiluminescent detection system (Pierce, IL, USA).
Densitometric analysis
Autoradiograms of the Western blots were scanned with Gel Doc 1000 image scanner (Bio-Rad, CA, USA) that was linked to a Macintosh computer. The bi-dimentional optical densities (O.D.) of p21 WAF1 , Bcl-2, Bax, p53 and actin proteins on the ®lms were quanti®ed and analyzed with Molecular Analyst software (Bio-Rad, CA, USA). The ratios of p21 WAF1 /actin, Bax/Bcl-2, and p53/actin were calculated with standardizing the ratios of each control to the unit value.
DNA ladder formation
Cellular cytoplasmic DNA from cells treated with 30 mM genistein for 24, 48 and 72 h or with Na 2 CO 3 for 48 h (as control), was extracted using 10 mM Tris (pH 8.0), 1 mM EDTA, and 0.2% Triton X-100. The lysate was centrifuged for 15 min at 13 000 g to separate the fragment DNA (soluble) from intact chromatin (nuclear pellet). The supernatant from the lysate was treated with RNase, followed by SDS-Proteinase K digestion, phenol chloroform extraction and isopropranol precipitation. DNA was separated through a 1.5% agarose gel. After electrophoresis, gels were stained with ethidium bromide and the DNA was visualized by UV light.
Analysis of cleavage of PARP
Cells treated with 30 mM genistein for 24, 48 and 74 h or with Na 2 CO 3 for 48 h (as control) were lysed in lysis buer (10 mM Tris-HCl (pH 7.1), 50 mM sodium chloride, 30 mM sodium pyrophosphate, 50 mM sodium¯uoride, 100 mM sodium orthovandate, 2 mM iodoacetic acid, 5 mM ZnCl 2 , 1 mM phenylmethylsulfonyl¯uoride, and 0.5% Triton X-100). The lysates were kept on ice for 30 min and vigorously vortexed before centrifugation at 12 500 g for 20 min. Fifty mg of total protein was resolved on 10% SDS ± PAGE and then transferred to nitrocellulose membrane. The membrane was incubated with primary monoclonal antihuman PARP antibody (1 : 5000, Biomol, PA, USA), washed with TTBS and incubated with secondary antibody conjugated with peroxidase. The signal was then detected using chemiluminescence detection system (Pierce, IL, USA).
Analysis of activation of CPP32
Cells treated with 30 mM genistein for 24, 48 and 72 h or with Na 2 CO 3 for 48 h (as control) were lysed in lysis buer (10 mM Tris-HCl (pH 7.1), 1 mM phenylmethylsulfonyl uoride, 2 mM dithiothreitol, and 1% Triton X-100). The lysates were kept on ice for 30 min and centrifuged at 12 500 g for 20 min. Fifty mg of total protein was resolved on 15% SDS ± PAGE and then transfererd to a nitrocellulose membrane. The membrane was incubated with primary monoclonal anti-human CPP32 antibody (1 : 200, Santa Cruz, CA, USA), washed with TTBS and incubated with secondary antibody conjugated with peroxidase. The signal was then detected using chemiluminescent detection system (Pierce, IL, USA).
Flow cytometry for detecting apoptosis
7-amino actinomycin D (7AAD) staining and¯ow cytometry was conducted to detect and quantify apoptosis (Philpott et al., 1996) . Cells treated with 30 mM genistin for 24, 48 and 72 h or with Na 2 CO 3 for 72 h (as control) were subjected to this analysis. Brie¯y, 7AAD (Calbiochem-Novabiochem, La Jolla, CA, USA) was dissolved in acetone and diluted in PBS to a concentration of 200 mg/ml. A total of 100 ml of 7AAD solution was added to 10 6 cells suspended in 1 ml PBS and mixed well. Cells were stained for 20 min at 48C while protected from light and pelleted by centrifugation. The cells were resuspended in 500 ml of 2% paraformaldehyde (PE) solution. Unstained ®xed cells were used as negative control. Samples were analysed on a FACscan (Becton Dickinson, CA, USA) within 30 min of ®xation. Data on 10 000 and 20 000 cells were acquired and processed using Lysys II software (Becton Dickinson, CA, USA). Scattergrams were generated by combining forward light scatter with 7AAD¯uorescence, and regions were drawn around clear-cut populations having negative, dim, and bright¯uorescence. The frequency of cells with low, medium and high 7AAD¯uorescence was assessed. The purity and enrichment of the sorted populations were then calculated.
